Form 4: Ocular Therapeutix Executive Receives Stock Grants and Options

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., was granted restricted stock units and stock options on October 2, 2024.

Summary

• Jeffrey S. Heier, the Chief Scientific Officer of Ocular Therapeutix, Inc., filed a Form 4 on October 4, 2024, reporting changes in beneficial ownership.
• On October 2, 2024, Heier was granted 100,000 restricted stock units (RSUs) under the company's 2021 Stock Incentive Plan.
• These RSUs will vest in equal annual installments over three years, starting on October 1, 2025, contingent upon continued service to the Corporation.
• Heier also received options to purchase 200,000 shares of common stock at an exercise price of $9.31 per share.
• These options vest over four years, with 1/48 of the shares vesting monthly beginning on November 1, 2024.
• Following these transactions, Heier directly owns 272,007 shares of Ocular Therapeutix common stock and options for 200,000 shares.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to executive compensation. It's neutral in tone and doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of RSUs and stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedules for both the RSUs and stock options incentivize continued service and contribution to the company's success.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry typically include a mix of salary, bonus, stock options, and restricted stock units.
• The vesting schedules for these equity grants are generally structured to incentivize long-term performance and retention, often over a period of three to five years.
• Companies like Regeneron, Vertex, and Alnylam also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The stock grants and options could potentially dilute existing shareholders if the options are exercised and the RSUs vest.
• The compensation package is designed to incentivize the Chief Scientific Officer to contribute to the company's long-term success, which would benefit all stakeholders.

Key Dates